France’s public healthcare system will now cover anti-obesity medications Wegovy and Mounjaro, but access is limited by strict eligibility criteria. This move acknowledges a growing obesity problem within the country, despite a long-held stereotype of French people maintaining a slim physique. While France historically has lower obesity rates than many other European Union nations, those numbers are increasing. The coverage of these drugs aims to address the health concerns associated with rising obesity levels. Regional disparities in obesity prevalence also exist within France, with certain areas experiencing higher rates than others. The decision reflects a shift in acknowledging and actively combating weight-related health issues in the nation.